Clinical trials: Schizophrenia Patients
Schizophrenia
A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients
The purpose of this study is to compare the efficacy and safety of ziprasidone and aripiprazole in hospitalized patients with schizophrenia or schizoaffective disorder
- Trial name
- NCT00634348
- Testing
- Aripiprazole, Ziprasidone
- Where
- 41 sites in United States
- Volunteers
- 256 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Recruitment, Invitation Letters, Patients With Schizophrenia
Recruitment of Patients Through Invitation Letters
Recruitment of patients with schizophrenia to clinical trials is difficult and in an ongoing project different methods of recruitment have been used in order to recruit.
- Trial name
- NCT03590015
- Testing
- Old invitation letter, New invitation Letter
- Where
- Denmark
- Volunteers
- 84 people
- Sponsor
- Aalborg University Hospital
Schizophrenia, Schizoaffective Disorders
Supervised Treatment of Schizophrenia, a Randomized Controlled Trial.
Patients suffering from Schizophrenia and their families often suffer from poor care because of ignorance about the disorder especially in economically developing countries.
- Trial name
- NCT00392249
- Testing
- Supervised Treatment of Schizophrenia by a family member
- Where
- Pakistan
- Volunteers
- 110 people
- Sponsor
- Lady Reading Hospital, Pakistan
Schizophrenia
An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients
This is an open label study of the treatment satisfaction, efficacy and tolerability of xanomeline/ trospium in a population of 172 participants diagnosed with schizophrenia in the early phase of illness.
- Trial name
- NCT06923891
- Testing
- Xanomeline/Trospium
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Vanguard Research Group
Schizophrenia
The Influence of Omega-3 Fatty Acid on the Violence of Schizophrenia Patient and the Possible Mechanism
Investigators plan to explore whether Omega-3 fatty acid have effect on the violent behavior of the schizophrenia patients. Investigators will use PET to explore the influence on serotonin function of the brain to understand the…
- Trial name
- NCT02552758
- Testing
- omega-3 fatty acid, positron emission tomography (PET)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia
Berberine Effect on Cytokine, CRP, Metabolic Disturbance as an Adjunctive Therapy in Schizophrenia Patients
The etiology and pathogenesis of schizophrenia remains unclear. Immune dysfunction hypothesis for schizophrenia has attracted increasing attention of the researchers, substantial evidences suggested the levels of C-reaction…
- Trial name
- NCT02936414
- Testing
- Berberine
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Tianjin Anding Hospital
Schizophrenia, Schizoaffective Disorder
Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients
In this study, we are going to investigate quantitative and qualitative natures of appetite and eating-behavior changes induced by atypical antipsychotics, i.e., risperidone, olanzapine and aripiprazole, in schizophrenia patients.
- Trial name
- NCT01043250
- Where
- South Korea
- Volunteers
- 81 people
- Sponsor
- Samsung Medical Center
Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia
The primary objective of this study was to continue to provide aripiprazole intramuscular (IM) depot treatment (400 milligrams [mg] or 300 mg) to participants with schizophrenia completing the 52-week, open-label safety and…
- Trial name
- ASPIRE (NCT01129882)
- Testing
- Aripiprazole
- Where
- 157 sites in United States, Argentina and 22 more
- Volunteers
- 709 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Digital Voice Analysis in Patients With Schizophrenia
There is a differences in voice frequency of schizophrenic patients compared to patients with other mental diseases and compared to mentally healthy people.
- Trial name
- NCT00524979
- Where
- Israel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BeerYaakov Mental Health Center
Major Depressive Disorder, Psychotic Disorders
A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00130676
- Testing
- Mifepristone
- Where
- 23 sites in United States
- Volunteers
- 257 people
- Sponsor
- Corcept Therapeutics
Schizophrenia, Schizoaffective Disorder
A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder
The purpose of the study is to compare the time to relapse in patients with schizophrenia and schizoaffective disorders receiving risperidone or haloperidol (antipsychotic medications) for at least 1 year.
- Trial name
- NCT00253110
- Testing
- risperidone, haloperidol
- Volunteers
- 396 people
- Sponsor
- Janssen, LP
Schizophrenia Spectrum and Other Psychotic Disorders
Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial
The aim of this study is to explore new safe effective psychotherapeutic interventions for schizophrenia through assessing the efficacy and acceptability of complementary "Insight Enhancement Program" (IEP) and "Metacognitive…
- Trial name
- NCT03955549
- Testing
- Insight Enhancement Program (IEP), Metacognitive Training for Psychosis (MCT), Treatment As Usual (TAU)
- Where
- Egypt
- Volunteers
- 99 people
- Sponsor
- Agiad Psychiatry Hospital
Schizophrenia, Chronic Psychiatric Disorder
Mental Healthcare in Older Adults With Schizophrenia
As in the general population, there is a gradual and steady increase in life expectancy of patients with schizophrenia. But this increase is at a smaller scale, with a rate of premature death that is still 2 to 3 times higher…
- Trial name
- CSA (NCT02884739)
- Testing
- Data collection
- Where
- France
- Volunteers
- 685 people
- Sponsor
- CHU de Reims
Schizophrenia, Psychotic Disorders
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
This is a randomized, single-dose, open-label, parallel-group study. Patients will undergo the screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- NCT05321602
- Testing
- LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid
- Where
- 9 sites in United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Marijuana Abuse, Psychotic Disorders
Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis
The purpose of the trial is to investigate the effect of specialized treatment of cannabis abuse among young people with psychosis. The specialized treatment consists of manualized individual treatment and group therapy.
- Conditions
- Marijuana Abuse, Psychotic Disorders, Schizophrenia
- Trial name
- CapOpus (NCT00484302)
- Testing
- Cognitive behavioral therapy with motivational interviewing, Non-manualized standard treatment
- Where
- Denmark
- Volunteers
- 103 people
- Sponsor
- Bispebjerg Hospital
Schizophrenia
Evaluate the Pharmacokinetics of Quetiapine Fumarate in Chinese Schizophrenic Patients
The primary objective of the study is to evaluate the pharmacokinetics of XR quetiapine fumarate(300mg,600mg,and 800mg once-daily) in Chinese schizophrenic patients .
- Trial name
- NCT00919607
- Testing
- quetiapine fumarate extended-release
- Where
- China
- Volunteers
- 31 people
- Sponsor
- AstraZeneca
Schizophrenia, Substance Use Disorders
The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients
The lifetime of substance use disorders in schizophrenia is close to 50%. Substance abuse in schizophrenia is associated with negative consequences.
- Trial name
- NCT00295412
- Testing
- quetiapine (drug)
- Where
- Canada
- Sponsor
- Université de Montréal
Tardive Dyskinesia
Pyridoxal Kinase Activity in Tardive Dyskinesia
Objectives: The mechanisms of tardive dyskinesia (TD) remain unclear, although pathophysiologic theories have proposed mechanisms such as dopamine receptor supersensitivity, the degeneration of cholinergic striatal interneurons…
- Trial name
- NCT01908452
- Testing
- Pyridoxine
- Where
- 3 sites in Israel
- Sponsor
- Beersheva Mental Health Center
Schizophrenia, Antipyretics Toxicity
Prolactin Change in Chinese Patients With Schizophrenia After Antipsychotics Treatment
Objective: Hyperprolactinemia(HPRL) which can result in a series of prolactin-related symptoms is a frequent adverse effect of antipsychotics.
- Conditions
- Schizophrenia, Antipyretics Toxicity, Prolactin Excess
- Trial name
- NCT04002258
- Testing
- Antipsychotic
- Where
- China
- Volunteers
- 10,363 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia
High-Definition Transcranial Direct Current Stimulation as a Treatment of Negative Symptoms of Schizophrenia
In this study, investigators designed a double-blind randomized trial to prove a more reliable evidence to show how the treatment by using high-definition transcranial direct current stimulation (HD-tDCS) can relieve negative…
- Trial name
- NCT03602716
- Testing
- HD-tDCS
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai Mental Health Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.